Compare Prudential Financial Inc (PRU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Repligen Corporation Common Stock — how do they compare? Prudential Financial Inc trades at $114.86 (market cap $39.15B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Prudential Financial Inc is far larger — about 3.5× Repligen Corporation Common Stock's market cap, and Prudential Financial Inc pays a 4.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 146 Days and Repligen Corporation Common Stock for 0 Days on average.
| PRU | RGEN | |
|---|---|---|
Market Cap | $39.15B | $11.31B |
Volume | 1,633,697 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $125.13 | $194.57 |
52-Week Low | $92.00 | $102.87 |
Typical Hold Time | 146 Days | 0 Days |
Enterprise Value | $67.93B | $11.20B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.41, showing minimal daily movement with a 0.02% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental metrics including a low P/E of 10.28 and solid ROE of 12.46%. Recent earnings show two consecutive beats, while the company executes strategic initiatives including a $185M Alexforbes stake sale and rebranding to Prudential Wealth Advisors.
PRU offers value investment appeal with attractive valuation multiples and consistent profitability, though technical weakness and mixed analyst sentiment (67.57% Hold rating) suggest near-term caution. Key risks include interest rate sensitivity and competitive pressures in the insurance sector, while higher rates could benefit investment income. The consensus price target of $105.56 implies modest downside from current levels.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
